Infinity Pharmaceuticals, Inc. provided unaudited earnings guidance for the full-year 2016. The company expects revenue for 2016 to range from $225 million to $245 million, assuming the achievement of $200 million in anticipated regulatory milestones under the company's collaboration with AbbVie: $125 million associated with the acceptance of the first NDA submission and $75 million associated with the acceptance of the first MAA submission, both expected in the fourth quarter of 2016. It expects net income for 2016 to range from $15 million to $35 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% |
|
0.00% | -99.96% |
25/03 | North American Morning Briefing : Tech in Focus on -2- | DJ |
25/03 | Infinity Pharmaceuticals, Inc. Went Out of Business | CI |
1st Jan change | Capi. | |
---|---|---|
-99.96% | 90 | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- INFI.Q Stock
- News Infinity Pharmaceuticals, Inc.
- Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full-Year 2016